Indian skincare startup Be Clinical has raised ₹6 crore in a seed funding round led by V3 Ventures, marking an important milestone in the brand’s early growth journey. The round also saw participation from Titan Capital, further strengthening investor confidence in the company’s science-led skincare approach.
The fresh capital comes at a time when India’s beauty and personal care market is witnessing rising demand for clinically proven, ingredient-focused skincare solutions. Be Clinical aims to tap into this shift by building products that focus on results, transparency, and evidence-based formulation.
Focus on Science-Backed Skincare Solutions
Founded in May 2025 by Hemangi Dhir, Be Clinical positions itself as a science-first skincare brand with a sharp focus on anti-ageing solutions. Unlike many cosmetic brands that rely heavily on marketing claims, Be Clinical emphasises in-vivo testing, clinical validation, and dermatologist-driven formulations.
The brand’s product portfolio spans face, body, and scalp care, targeting age-related concerns through active ingredients that are carefully dosed and tested for visible results. By prioritising research and efficacy, the company aims to build long-term consumer trust in a market that has traditionally been sceptical about performance claims.
How the Funding Will Be Utilised
According to the company, the newly raised funds will be primarily channelled into strengthening its research and development capabilities. Be Clinical plans to invest significantly in expanding its in-house formulation team and increasing the scope of clinical testing across existing and upcoming products.
A portion of the funding will also be used to enhance manufacturing infrastructure. This includes the addition of new machinery to improve production efficiency, ensure quality consistency, and support scale-up as demand grows. Improving packaging formats is another key focus area, with the brand aiming to adopt packaging that better preserves ingredient stability while reinforcing its clinical positioning.
Early Traction and Growing Consumer Base
Despite being a young brand, Be Clinical has already demonstrated promising early traction. The company claims to have served over 25,000 customers in a short span of time, indicating a growing acceptance of clinically driven skincare among Indian consumers.
This early adoption reflects a broader trend where customers are increasingly educated about ingredients, formulations, and product safety. Consumers today are actively seeking brands that offer clarity on what goes into their skincare routine, and Be Clinical appears well-placed to benefit from this shift.
Addressing Gaps in the Indian Skincare Market
India’s skincare industry has long been dominated by mass-market products and international brands that may not always cater specifically to Indian skin types or climatic conditions. Be Clinical aims to bridge this gap by developing products tailored for local needs, while maintaining global clinical standards.
The brand competes in a crowded segment that includes both legacy global players and fast-growing Indian direct-to-consumer brands. Its differentiation lies in its strong emphasis on measurable outcomes rather than cosmetic promises, which could help it carve a distinct niche in the premium, results-oriented skincare space.
What This Funding Means Going Ahead
The seed funding led by V3 Ventures signals strong investor belief in science-backed consumer brands in India. With fresh capital in hand, Be Clinical is expected to accelerate product innovation, improve operational efficiency, and deepen its engagement with consumers who value evidence-led skincare.
As the Indian beauty market continues to evolve, brands that combine scientific rigour with consumer education are likely to gain long-term relevance. Be Clinical’s latest fundraise positions it well to scale thoughtfully while staying true to its clinical foundation and product-first philosophy.